Mark Blumling is an Executive Advisor at New Mountain Capital. Mark is the former CEO and Founder of Headlands Research, a KKR-backed clinical research site company. Mark was previously CEO and Co-Founder of Genos, a big data healthcare technology company (acquired in 2017) and CEO of Relevare Pharmaceuticals, a pharmaceutical company based in San Francisco and Melbourne, Australia. Prior to joining Relevare, Mark was Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired in 2015) as well as a Director at Burrill & Company, where he worked in private equity, venture capital, and investment banking. Mark began his career in the Office of Science & Technology (R&D) at SmithKline Beecham, where he was involved in the creation and development of new business ventures, and at Orchid Biosciences (NASDAQ: ORCH).

Mark received a JD from Stanford Law School, an MSc (Economics) from the London School of Economics, and a BA in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.